Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Zai Lab Limited (NASDAQ: ZLAB ) continues to develop treatments for oncology, autoimmune disorders, infectious diseases, and neurological conditions. In my view, their most important value driver today is Vyvgart for generalized myasthenia gravis [gMG], which showed significant revenue growth in 2024. Also, the recent approval in ChinaMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degre ...